Mga Batayang Estadistika
| CIK | 1043873 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to GraniteShares ETF Trust - GraniteShares 2x Long NVDA Daily ETF
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| March 30, 2012 |
15-12G 1 c6910415-12g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-32177 NovaDel Pharma Inc. (Exact name of regis |
|
| March 21, 2012 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 20, 2012 NOVADEL PHARMA INC. |
|
| March 21, 2012 |
NOVADEL PHARMA INC. SUMMARY STATEMENT OF OPERATIONS UNAUDITED THREE MONTHS ENDED Exhibit 99.1 NovaDel Reports Unaudited Financial Results for Fourth Quarter and Year Ended December 31, 2011 BRIDGEWATER, N.J.— March 20, 2012 — NovaDel Pharma Inc. (OTC BB: NVDL) today reported unaudited financial results for the fourth quarter and year ended December 31, 2011. The company does not have, at this time, sufficient financial resources to fund an audit of these financial statements. |
|
| February 13, 2012 |
NVDL / NovaDel Pharma, Inc. / PROQUEST INVESTMENTS II LP - FORM SC 13D/A Activist Investment SC 13D/A 1 formsc13da1526063.htm FORM SC 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6)* NovaDel Pharma Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 66986X 10 6 (CUSIP Number) Pasquale DeAngelis ProQuest Investments 90 Nassau Street, 5th Floor Princeton, NJ 08542-4520 (609) 919-3560 (Name |
|
| February 8, 2012 |
EX-10.1 2 c68426ex10-1.htm Exhibit 10.1 CONFIDENTIAL BINDING TERM SHEET FOR ACQUISITION OF CERTAIN NITROMIST™ ASSETS OF NOVADEL PHARMA, INC. BY APRICUS BIOSCIENCES, INC (“TERM SHEET”) February 2, 2012 1. Parties (a) Apricus Biosciences, Inc., a Nevada corporation with its principal address at 11975 El Camino Real, Suite 300 San Diego, CA 92130(“Buyer”); and (b) NovaDel Pharma, Inc., a Delaware cor |
|
| February 8, 2012 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 c684268-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 2, 2012 NOVADEL PHARMA INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-32177 22-2407152 (State or other jurisdiction of incorporati |
|
| February 1, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 30, 2012 NOVADEL PHARMA INC. |
|
| January 31, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K/A (Amendment No. |
|
| January 20, 2012 |
NovaDel Announces Termination of License Agreements for Ondansetron Oral Spray Product Exhibit 99.1 NovaDel Announces Termination of License Agreements for Ondansetron Oral Spray Product Bridgewater, NJ – January 20, 2012 - NovaDel Pharma Inc. (OTCBB: NVDL), a specialty pharmaceutical company that develops oral spray formulations of marketed pharmaceutical products, today announced the termination of certain license agreements with Talon Therapeutics, Inc. and Par Pharmaceutical Com |
|
| January 20, 2012 |
Termination of a Material Definitive Agreement, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 16, 2012 NOVADEL PHARMA INC. |
|
| January 20, 2012 |
TERMINATION AGREEMENT AND MUTUAL RELEASE Exhibit 10.1 EXECUTION VERSION TERMINATION AGREEMENT AND MUTUAL RELEASE This TERMINATION AGREEMENT AND MUTUAL RELEASE (this “Agreement”) is made and entered into by and among Par Pharmaceutical, Inc., a Delaware corporation (“Par”), Talon Therapeutics, Inc. (formerly Hana Biosciences, Inc.) a Delaware corporation (“Talon”), and NovaDel Pharma, Inc., a Delaware corporation (“NovaDel”), effective as |
|
| January 19, 2012 |
AMENDED AND RESTATED BY-LAWS NOVADEL PHARMA INC. (a Delaware corporation) ARTICLE I OFFICES Ex-3.1 AMENDED AND RESTATED BY-LAWS OF - NOVADEL PHARMA INC. (a Delaware corporation) - ARTICLE I OFFICES The registered office of NovaDel Pharma Inc. (the “Corporation”) shall be located in Wilmington, Delaware. The principal office of the Corporation shall be in the City of Bridgewater, County of Somerset, State of New Jersey. The Corporation may also have offices at such other places within or |
|
| January 19, 2012 |
EX-17.3 6 c68166ex17-3.htm Ex-17.3 January 12, 2012 Mr. Steven B. Ratoff President and Chief Executive Officer NovaDel Pharma 1200 Route 22 East, Suite 2000 Bridgewater, New Jersey 08807 Dear Steve, Please accept my resignation from the Board of Directors of NovaDel Pharma, effective immediately. Sincerely, /s/ Charles B. Nemeroff Charles B. Nemeroff, M.D., Ph.D. Cc: Mr. Mark J. Baric Mr. Thomas B |
|
| January 19, 2012 |
EX-17.1 4 c68166ex17-1.htm Ex-17.1 January 12, 2012 Steven B. Ratoff President and CEO Chairman of the Board NovaDel Pharma, Inc. Steve, Effective immediately, I heareby resign from the Board of Directors of NovaDel Pharma, Inc, and any and all committees of the Board of Directors in which I am a member. It has been a pleasure working with you and the Novadel team. Best wishes for success with the |
|
| January 19, 2012 |
AMENDED AND RESTATED BY-LAWS NOVADEL PHARMA INC. (a Delaware corporation) ARTICLE I OFFICES EX-3.2 3 c68166ex3-2.htm Exhibit 3.2 AMENDED AND RESTATED BY-LAWS OF NOVADEL PHARMA INC. (a Delaware corporation) ARTICLE I OFFICES The registered office of NovaDel Pharma Inc. (the “Corporation”) shall be located in Wilmington, Delaware. The principal office of the Corporation shall be in the City of FlemingtonBridgewater, County of HunterdonSomerset, State of New Jersey. The Corporation may also |
|
| January 19, 2012 |
NovaDel Continuing to Explore Strategic Alternatives Ex-99.1 NovaDel Continuing to Explore Strategic Alternatives Bridgewater, NJ – January 18, 2012 - NovaDel Pharma Inc. (OTCBB: NVDL), a specialty pharmaceutical company that develops oral spray formulations of marketed pharmaceutical products, today announced that, as previously disclosed, it is continuing to explore various strategic alternatives for the Company, including selling the Company or s |
|
| January 19, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 12, 2012 NOVADEL PHARMA INC. |
|
| January 19, 2012 |
EX-17.2 5 c68166ex17-2.htm Ex-17.2 January 12, 2012 Board of Directors NovaDel Pharma Inc. 1200 Route 22 East, Suite 2000 Bridgewater, New Jersey 08807 Gentlemen: Effective immediately, please accept my resignation as a member of the Board of Directors of NovaDel Pharma Inc. (the “Company”) as well as my positions on the committees of the Board of Directors of the Company. Very truly yours, /s/ Th |
|
| November 14, 2011 |
EX-99.1 2 exhibit99.htm LETTER AGREEMENT Exhibit 99.1 VELCERA October 27, 2011 Stephen B. Ratoff President, Chief Executive Officer NovaDel Pharma, Inc. 1200 Route 22 East, Suite 2000 Bridgewater, New Jersey 08807 RE: Settlement of Claims Arising Under June 22, 2004 Second Amendment to License and Development Agreement by and between NovaDel Pharma, Inc. (“NovaDel") and The Veterinary Company, Inc |
|
| November 14, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 2, 2011 NOVADEL PHARMA INC. |
|
| November 1, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 1, 2011 NOVADEL PHARMA INC. |
|
| November 1, 2011 |
EX-10.2 2 d236411dex102.htm LICENSE AND DISTRIBUTION AGREEMENT Exhibit 10.2 Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as “***”. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission. LICENSE AGREEMENT THIS LI |
|
| November 1, 2011 |
424B3 1 d248529d424b3.htm PROSPECTUS SUPPLEMENT Table of Contents Prospectus Supplement filed pursuant to Rule 424(b)(3) Registration Statement No. 333-170066 PROSPECTUS SUPPLEMENT NO. 2 DATED NOVEMBER 1, 2011 (To Prospectus Dated June 7, 2011) NOVADEL PHARMA INC. This is a supplement (“Prospectus Supplement No. 2”) to our prospectus, dated June 7, 2011 (the “Prospectus”), relating to the offer an |
|
| November 1, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2011 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . COMMISSION FILE NO. |
|
| November 1, 2011 |
NovaDel Reports Financial Results for Third Quarter 2011 EX-99.1 2 exhibit99.htm PRESS RELEASE Exhibit 99.1 NovaDel Reports Financial Results for Third Quarter 2011 Bridgewater, NJ – November 1, 2011 - NovaDel Pharma Inc. (OTCBB: NVDL), a specialty pharmaceutical company that develops oral spray formulations of marketed pharmaceutical products, today reported financial results for the quarter ended September 30, 2011. As of September 30, 2011, NovaDel’s |
|
| November 1, 2011 |
424B3 1 d248533d424b3.htm PROSPECTUS SUPPLEMENT Table of Contents Prospectus Supplement filed under Rule 424(b)(3) in connection with Registration No. 333-167425 PROSPECTUS SUPPLEMENT NO. 3 DATED NOVEMBER 1, 2011 (To Prospectus Dated April 12, 2011) NOVADEL PHARMA INC. This is a supplement (“Prospectus Supplement No. 3”) to our prospectus, dated April 12, 2011 (the “Prospectus”), relating to the o |
|
| August 31, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 30, 2011 NOVADEL PHARMA INC. |
|
| August 31, 2011 |
Exhibit 99.1 Recent Events Bridgewater, NJ – August 30, 2011 - NovaDel Pharma Inc. (OTCBB: NVDL), a specialty pharmaceutical company that develops oral spray formulations of marketed pharmaceutical products, as previously reported, recently initiated its clinical development program for Duromist®, its oral spray formulation of sildenafil citrate, for use in erectile dysfunction (ED). The recent de |
|
| August 22, 2011 |
Exhibit 99.1 NovaDel Signs Exclusive License and Distribution Agreement with Rechon Life Science AB to Manufacture and Commercialize Zolpimist® outside the US and Canada Bridgewater, NJ – August 22, 2011 - NovaDel Pharma Inc. (OTC BB: NVDL), a specialty pharmaceutical company that develops oral spray formulations of marketed pharmaceutical products, today announced its entry into an exclusive lice |
|
| August 22, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 18, 2011 NOVADEL PHARMA INC. |
|
| August 12, 2011 |
Prospectus Supplement filed under Rule 424(b)(3) in connection with Registration No. |
|
| August 12, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2011 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . COMMISSION FILE NO. 001- |
|
| August 12, 2011 |
Prospectus Supplement filed pursuant to Rule 424(b)(3) Registration Statement No. 333-170066 PROSPECTUS SUPPLEMENT NO. 1 DATED AUGUST 12, 2011 (To Prospectus Dated June 7, 2011) NOVADEL PHARMA INC. This is a supplement (“Prospectus Supplement No. 1”) to our prospectus, dated June 7, 2011 (the “Prospectus”), relating to the offer and sale of 1,667 shares of our Series A Convertible Preferred Stock, |
|
| August 12, 2011 |
NovaDel Reports Financial Results for Second Quarter 2011 EX-99.1 2 exhibit9981211.htm PRESS RELEASE Exhibit 99.1 NovaDel Reports Financial Results for Second Quarter 2011 Bridgewater, NJ – August 12, 2011 - NovaDel Pharma Inc. (OTC BB: NVDL), a specialty pharmaceutical company that develops oral spray formulations of marketed pharmaceutical products, today reported financial results for the quarter ended June 30, 2011. As of June 30, 2011, NovaDel’s cas |
|
| August 12, 2011 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 12, 2011 NOVADEL PHARMA INC. |
|
| August 12, 2011 |
EX-3.1 2 dex31.htm CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION Exhibit 3.1 CERTIFICATE OF AMENDMENT OF THE RESTATED CERTIFICATE OF INCORPORATION OF NOVADEL PHARMA INC. Pursuant to Sections 141 and 242 of the Delaware General Corporation Law NovaDel Pharma Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State |
|
| July 8, 2011 |
8-K 1 form8k7611.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 5, 2011 NOVADEL PHARMA INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-32177 22-2407152 (State or other jurisdiction of |
|
| July 8, 2011 |
AMENDMENT TO EMPLOYMENT AGREEMENT EX-10.1 2 exhibit10-1.htm AMENDMENT Exhibit 10.1 AMENDMENT TO EMPLOYMENT AGREEMENT THIS AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”), effective as of June 30, 2011, is entered into as of July 5, 2011, by and between NOVADEL PHARMA INC., a Delaware corporation with principal executive offices at 1200 Route 22 East, Suite 2000, Bridgewater, New Jersey 08807 (the “Company”), and DAVID H. BERG |
|
| June 27, 2011 |
EX-99.1 2 exhibit99-1.htm PRESENTATION NovaDel Pharma Inc. Positioned for Growth NVDL.OB Forward Looking Statement Except for historical information contained herein, this presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks and uncertainties that may cause the Company's actu |
|
| June 27, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 23, 2011 NOVADEL PHARMA INC. |
|
| June 9, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 6, 2011 NOVADEL PHARMA INC. |
|
| June 9, 2011 |
NovaDel Announces Changes in Management EX-99.1 2 exhibit99.htm PRESS RELEASE Exhibit 99.l NovaDel Announces Changes in Management Bridgewater, NJ – June 9, 2011 - NovaDel Pharma Inc. (OTC BB: NVDL), a specialty pharmaceutical company that develops oral spray formulations of marketed pharmaceutical products, announced today that Mr. Craig A. Johnson advised the Company of his resignation as Senior Vice President, Chief Financial Officer |
|
| June 8, 2011 |
Prospectus Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-170066 1,667 SHARES OF SERIES A CONVERTIBLE PREFERRED STOCK, TOGETHER WITH SERIES A WARRANTS TO PURCHASE 16,670,000 SHARES OF COMMON STOCK, SERIES B WARRANTS TO PURCHASE 16,670,000 SHARES OF COMMON STOCK, SERIES C WARRANTS TO PURCHASE 16,670,000 SHARES OF COMMON STOCK AND UP TO 40,000,000 SHARES OF COMMON STOCK UNDERLYING T |
|
| June 6, 2011 |
1200 Route 22 East, Suite 2000 Bridgewater, NJ 08807 (908) 203-4640 June 6, 2011 VIA FACSIMILE & EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| June 2, 2011 |
NovaDel Reports Opening of Duromist™ original IND with FDA EX-99.1 2 exhibit99.htm PRESS RELEASE Exhibit 99.1 NovaDel Reports Opening of Duromist™ original IND with FDA Bridgewater, NJ – June 2, 2011 - NovaDel Pharma Inc. (OTC BB: NVDL), a specialty pharmaceutical company that develops oral spray formulations of marketed pharmaceutical products, today reported opening an original Investigational New Drug (IND) application with the United States Food and D |
|
| June 2, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) June 2, 2011 NOVADEL PHARMA INC. |
|
| May 31, 2011 |
EX-10.1 2 exhibit10-1.htm FORM OF CONSENT AGREEMENT Exhibit 10.1 CONSENT AGREEMENT This Consent Agreement (this “Agreement”) is made and entered into as of the 31st day of May, 2011 (the “Effective Date”) by and among NovaDel Pharma Inc., a Delaware corporation (the “Company”) and the undersigned (the “Investor”). Capitalized terms used but not defined herein shall have the meaning set forth in th |
|
| May 31, 2011 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 31, 2011 NOVADEL PHARMA INC. |
|
| May 31, 2011 |
As filed with the Securities and Exchange Commission on May 31, 2011 As filed with the Securities and Exchange Commission on May 31, 2011 Registration Statement No. |
|
| May 31, 2011 |
May 31, 2011 VIA EDGAR AND FEDERAL EXPRESS Mr. Jeffrey P. Riedler Assistant Director Securities and Exchange Commission 100 F Street, N.E., Mail Stop 4720 Washington, DC 20549 Re: NovaDel Pharma Inc. Post-Effective Amendment to Registration Statement on Form S-1 Filed April 4, 2011 File No.: 333-170066 (the “Registration Statement”) Dear Mr. Riedler: On behalf of NovaDel Pharma Inc. (the “Company” |
|
| May 17, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confide |
|
| May 16, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 10-Q 1 novadel10q33111.htm QUARTERLY REPORT Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2011 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transit |
|
| May 16, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 16, 2011 NOVADEL PHARMA INC. |
|
| May 16, 2011 |
NovaDel Reports Financial Results for First Quarter 2011 EX-99.1 2 exhibit99.htm PRESS RELEASE Exhibit 99.1 NovaDel Reports Financial Results for First Quarter 2011 Bridgewater, NJ – May 16, 2011 - NovaDel Pharma Inc. (OTC BB: NVDL), a specialty pharmaceutical company that develops oral spray formulations of marketed pharmaceutical products, today reported financial results for its first quarter ended March 31, 2011. As of March 31, 2011, NovaDel’s cash |
|
| May 16, 2011 |
Prospectus Supplement filed pursuant to Rule 424(b)(3) Registration Statement No. 333-167425 PROSPECTUS SUPPLEMENT NO. 1 DATED MAY 16, 2011 (To Prospectus Dated April 12, 2011) NOVADEL PHARMA INC. This is a supplement (“Prospectus Supplement No. 1”) to our prospectus, dated April 12, 2011 (the “Prospectus”), relating to the offer and sale by certain selling securities holders of up to 7,583,335 sh |
|
| May 2, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confide |
|
| April 25, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2010 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NO. 001-32177 NOVADEL PHARMA INC. (Exact Name of registrant as |
|
| April 4, 2011 |
As filed with the Securities and Exchange Commission on April 1, 2011 As filed with the Securities and Exchange Commission on April 1, 2011 Registration Statement No. |
|
| April 4, 2011 |
As filed with the Securities and Exchange Commission on April 1, 2011 As filed with the Securities and Exchange Commission on April 1, 2011 Registration Statement No. |
|
| April 4, 2011 |
April 4, 2011 VIA EDGAR Securities and Exchange Commission 100 F Street, N.E., Mail Stop 4720 Washington, DC 20549 Re: NovaDel Pharma Inc. Request to Withdraw Pre-Effective Amendments to Form S-1 (File No. 333-167425 and File No. 333-170066) Form A-W Application for Withdrawal Ladies and Gentlemen: Pursuant to Rule 477 promulgated under the Securities Act of 1933, as amended (the “Securities Act”) |
|
| April 4, 2011 |
AW 1 formaw2.htm APPLICATION FOR WITHDRAWAL April 4, 2011 VIA EDGAR Securities and Exchange Commission 100 F Street, N.E., Mail Stop 4720 Washington, DC 20549 Re: NovaDel Pharma Inc. Request to Withdraw Pre-Effective Amendments to Form S-1 (File No. 333-167425 and File No. 333-170066) Form A-W Application for Withdrawal Ladies and Gentlemen: Pursuant to Rule 477 promulgated under the Securities Ac |
|
| April 4, 2011 |
As filed with the Securities and Exchange Commission on April 1, 2011 As filed with the Securities and Exchange Commission on April 1, 2011 Registration Statement No. |
|
| April 4, 2011 |
As filed with the Securities and Exchange Commission on April 1, 2011 As filed with the Securities and Exchange Commission on April 1, 2011 Registration Statement No. |
|
| March 29, 2011 |
NovaDel Reports Financial Results for Year Ended December 31, 2010 EX-99.1 2 exhibit99.htm PRESS RELEASE Exhibit 99.1 NovaDel Reports Financial Results for Year Ended December 31, 2010 Bridgewater, NJ – March 29, 2011 - NovaDel Pharma Inc. (OTC BB: NVDL), a specialty pharmaceutical company that develops oral spray formulations of marketed pharmaceutical products, today reported financial results for the year ended December 31, 2010. Financial Results For the year |
|
| March 29, 2011 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [ X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2010 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NO. 001-32177 NOVADEL PHARMA INC. (Exact Name of registrant a |
|
| March 29, 2011 |
EX-10.32 2 exhibit10-32.htm AGREEMENT Exhibit 10.32 LICENSE AGREEMENT This License Agreement (“Agreement”), effective as of January 5, 2007 (“Effective Date”), is between NovaDel Pharma, Inc., a Delaware corporation located at 25 Minneakoning Road, Flemington, NJ, 08822 USA (“Licensor”), and Kwang Dong Pharmaceuticals, a corporation duly organized and existing under the laws of the Republic of Kor |
|
| March 29, 2011 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 29, 2011 NOVADEL PHARMA INC. |
|
| March 24, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 NOVADEL PHARMA INC. (Exact name of registrant as specified in its charter) Delaware (State of incorporation or organization) 22-2407152 (I.R.S. Employer Identification No.) 1200 ROUTE 22 EAST, SUIT |
|
| February 15, 2011 |
CERTIFICATE OF DESIGNATIONS OF THE SERIES A CONVERTIBLE PREFERRED STOCK OF NOVADEL PHARMA INC. Exhibit 3.1 CERTIFICATE OF DESIGNATIONS OF THE SERIES A CONVERTIBLE PREFERRED STOCK OF NOVADEL PHARMA INC. I, Steve Ratoff, hereby certify that I am the President and Chief Executive Officer of NovaDel Pharma Inc. (the “Company”), a corporation organized and existing under the Delaware General Corporation Law (the “DGCL”), and further do hereby certify: That pursuant to the authority expressly con |
|
| February 15, 2011 |
[FORM OF SERIES B WARRANT] NOVADEL PHARMA INC. WARRANT TO PURCHASE COMMON STOCK Exhibit 4.3 [FORM OF SERIES B WARRANT] NOVADEL PHARMA INC. WARRANT TO PURCHASE COMMON STOCK Series B Warrant No.: Date of Issuance: February [], 2011 (“Issuance Date”) NovaDel Pharma Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [IROQUOIS MASTER FUND LTD.], [OTHER BUYERS], the |
|
| February 15, 2011 |
424B4 1 c63032424b4.htm Filed pursuant to Rule 424(b)(4) Registration Statement No. 333-170066 PROSPECTUS 1,667 SHARES OF SERIES A CONVERTIBLE PREFERRED STOCK, TOGETHER WITH SERIES A WARRANTS TO PURCHASE 16,670,000 SHARES OF COMMON STOCK, SERIES B WARRANTS TO PURCHASE 16,670,000 SHARES OF COMMON STOCK, SERIES C WARRANTS TO PURCHASE 16,670,000 SHARES OF COMMON STOCK AND UP TO 40,000,000 SHARES OF C |
|
| February 15, 2011 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 14, 2011 NOVADEL PHARMA INC. |
|
| February 15, 2011 |
Exhibit 1.1 NOVADEL PHARMA INC. 1,667 Shares Series A Convertible Preferred Stock Series A Warrants to Purchase up to 16,670,000 Shares of Common Stock Series B Warrants to Purchase up to 16,670,000 Shares of Common Stock Series C Warrants to Purchase up to 16,670,000 Shares of Common Stock PLACEMENT AGENCY AGREEMENT February 14, 2011 Roth Capital Partners, LLC 24 Corporate Plaza Newport Beach, Ca |
|
| February 15, 2011 |
NovaDel Announces $1.6 Million Equity Financing Exhibit 99.1 NovaDel Announces $1.6 Million Equity Financing Bridgewater, NJ – February 15, 2011 NovaDel Pharma Inc. (OTCBB: NVDL.OB) announced today that it entered into a securities purchase agreement to raise $1.6 million in gross proceeds through the sale of 1,667 shares of its Series A Convertible Preferred Stock to institutional investors having a stated value of $1,000 per share for a price |
|
| February 15, 2011 |
PLACEMENT AGENT WARRANT NOVADEL PHARMA INC. WARRANT TO PURCHASE COMMON STOCK Exhibit 4.5 PLACEMENT AGENT WARRANT NOVADEL PHARMA INC. WARRANT TO PURCHASE COMMON STOCK Warrant No.: PA-4 Date of Issuance: February 14, 2011 (“Issuance Date”) NovaDel Pharma Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Roth Capital Partners, LLC, the registered holder hereof |
|
| February 15, 2011 |
See Legends on Reverse Incorporated Under the Laws of the State of Delaware EXHIBIT 4.1 See Legends on Reverse Incorporated Under the Laws of the State of Delaware ******* ******* NOVADEL PHARMA INC. SERIES A CONVERTIBLE PREFERRED STOCK $0.001PAR VALUE THIS IS TO CERTIFY THAT is the owner of () Shares of the SERIES A CONVERTIBLE PREFERRED STOCK OF NOVADEL PHARMA INC. transferable only on the books of the Corporation by the holder hereof, in person or by attorney, upon sur |
|
| February 15, 2011 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of February 14, 2011, is by and among NovaDel Pharma Inc., a Delaware corporation with headquarters located at 1200 Route 22 East, Suite 2000, Bridgewater, New Jersey 08807 (the ”Company”), and each of the investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” and |
|
| February 15, 2011 |
[FORM OF SERIES A WARRANT] NOVADEL PHARMA INC. WARRANT TO PURCHASE COMMON STOCK Exhibit 4.2 [FORM OF SERIES A WARRANT] NOVADEL PHARMA INC. WARRANT TO PURCHASE COMMON STOCK Series A Warrant No.: Date of Issuance: February [], 2011 (“Issuance Date”) NovaDel Pharma Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [IROQUOIS MASTER FUND LTD.], [OTHER BUYERS], the |
|
| February 15, 2011 |
[FORM OF SERIES C WARRANT] NOVADEL PHARMA INC. WARRANT TO PURCHASE COMMON STOCK Exhibit 4.4 [FORM OF SERIES C WARRANT] NOVADEL PHARMA INC. WARRANT TO PURCHASE COMMON STOCK Series C Warrant No.: Date of Issuance: February [], 2011 (“Issuance Date”) NovaDel Pharma Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [IROQUOIS MASTER FUND LTD.], [OTHER BUYERS], the |
|
| February 11, 2011 |
Roth Capital Partners, LLC 24 Corporate Plaza Newport Beach, CA 92660 novadelaccelerationrequestex.htm - Converted by SEC Publisher, created by BCL Technologies Inc., for SEC Filing Roth Capital Partners, LLC 24 Corporate Plaza Newport Beach, CA 92660 February 11, 2011 Securities and Exchange Commission 100 F Street, N.W. Washington, D.C. 20549 Re: NovaDel Pharma Inc. (the “Company”) Registration Statement on Form S-1 (File No. 333-170066) Ladies and Gentlemen: In c |
|
| February 10, 2011 |
[FORM OF SERIES B WARRANT] NOVADEL PHARMA INC. WARRANT TO PURCHASE COMMON STOCK EXHIBIT 4.7 FOR NEGOTIATION AND DISCUSSION PURPOSES ONLY NOT AN OFFER OR SALE OF SECURITIES [FORM OF SERIES B WARRANT] NOVADEL PHARMA INC. WARRANT TO PURCHASE COMMON STOCK Series B Warrant No.: Date of Issuance: February [], 2011 (“Issuance Date”) NovaDel Pharma Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of |
|
| February 10, 2011 |
EXHIBIT 1.1 NOVADEL PHARMA INC. ● Shares Series ● Preferred Stock Series A Warrants to Purchase up to ● Shares of Common Stock Series B Warrants to Purchase up to ● Shares of Common Stock Series C Warrants to Purchase up to ● Shares of Common Stock PLACEMENT AGENCY AGREEMENT February ●, 2011 Roth Capital Partners, LLC 24 Corporate Plaza Newport Beach, California 92660 Dear Sirs: NovaDel Pharma, In |
|
| February 10, 2011 |
See Legends on Reverse Incorporated Under the Laws of the State of Delaware EXHIBIT 4.5 See Legends on Reverse Incorporated Under the Laws of the State of Delaware ******* ******* NOVADEL PHARMA INC. SERIES A CONVERTIBLE PREFERRED STOCK $0.001PAR VALUE THIS IS TO CERTIFY THAT is the owner of () Shares of the SERIES A CONVERTIBLE PREFERRED STOCK OF NOVADEL PHARMA INC. transferable only on the books of the Corporation by the holder hereof, in person or by attorney, upon sur |
|
| February 10, 2011 |
EXHIBIT 10.32 FOR NEGOTIATION AND DISCUSSION PURPOSES ONLY NOT AN OFFER OR SALE OF SECURITIES SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of February [], 2011, is by and among NovaDel Pharma Inc., a Delaware corporation with headquarters located at 1200 Route 22 East, Suite 2000, Bridgewater, New Jersey 08807 (the “Company”), and each of the investo |
|
| February 10, 2011 |
EXHIBIT 3.4 CERTIFICATE OF DESIGNATIONS, PREFERENCES AND RIGHTS OF THE SERIES A CONVERTIBLE PREFERRED STOCK OF NOVADEL PHARMA INC. I, [], hereby certify that I am the [] and [] of NovaDel Pharma Inc. (the “Company”), a corporation organized and existing under the Delaware General Corporation Law (the “DGCL”), and further do hereby certify: That pursuant to the authority expressly conferred upon th |
|
| February 10, 2011 |
As filed with the Securities and Exchange Commission on February 10, 2011 As filed with the Securities and Exchange Commission on February 10, 2011 Registration Statement No. |
|
| February 10, 2011 |
[FORM OF SERIES A WARRANT] NOVADEL PHARMA INC. WARRANT TO PURCHASE COMMON STOCK EXHIBIT 4.6 FOR NEGOTIATION AND DISCUSSION PURPOSES ONLY NOT AN OFFER OR SALE OF SECURITIES [FORM OF SERIES A WARRANT] NOVADEL PHARMA INC. WARRANT TO PURCHASE COMMON STOCK Series A Warrant No.: Date of Issuance: February [], 2011 (“Issuance Date”) NovaDel Pharma Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of |
|
| February 10, 2011 |
[FORM OF SERIES C WARRANT] NOVADEL PHARMA INC. WARRANT TO PURCHASE COMMON STOCK EXHIBIT 4.8 FOR NEGOTIATION AND DISCUSSION PURPOSES ONLY NOT AN OFFER OR SALE OF SECURITIES [FORM OF SERIES C WARRANT] NOVADEL PHARMA INC. WARRANT TO PURCHASE COMMON STOCK Series C Warrant No.: Date of Issuance: February [], 2011 (“Issuance Date”) NovaDel Pharma Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of |
|
| February 10, 2011 |
[NOVADEL LETTERHEAD] February 10, 2011 VIA FACSIMILE & EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| February 4, 2011 |
Zolpimist™ Oral Spray Launched in United States Exhibit 99.1 Zolpimist™ Oral Spray Launched in United States Bridgewater, NJ – February 4, 2011 – NovaDel Pharma Inc. (OTCBB: NVDL) today announced that Zolpimist Oral Spray has been launched in the United States by ECR Pharmaceuticals, a subsidiary of Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK). ECR Pharmaceuticals announced the immediate availability of Zolpimist Oral Spray, a novel delivery syst |
|
| February 4, 2011 |
As filed with the Securities and Exchange Commission on February 4, 2011 3B2 EDGAR HTML - c63032preflight.htm As filed with the Securities and Exchange Commission on February 4, 2011 Registration Statement No. 333-170066 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 3 to Form S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NOVADEL PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Delaware 2834 22-2407 |
|
| February 4, 2011 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 4, 2011 NOVADEL PHARMA INC. |
|
| January 14, 2011 |
As filed with the Securities and Exchange Commission on January 14, 2011 3B2 EDGAR HTML - c63032preflight.htm As filed with the Securities and Exchange Commission on January 14, 2011 Registration Statement No. 333-170066 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 2 to Form S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NOVADEL PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Delaware 2834 22-2407 |
|
| January 7, 2011 |
NovaDel Pharma Inc. Receives $500,000 Milestone Payment NitroMist® Launched in United States Exhibit 99.1 NovaDel Pharma Inc. Receives $500,000 Milestone Payment NitroMist® Launched in United States Bridgewater, NJ – January 7, 2011 – NovaDel Pharma Inc. (OTCBB: NVDL) today announced that it has received a $500,000 milestone payment from Akrimax Pharmaceuticals. The milestone payment was received in connection with the license and distribution agreement, dated October 27, 2009, between No |
|
| January 7, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 7, 2011 NOVADEL PHARMA INC. |
|
| January 5, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 5, 2011 NOVADEL PHARMA INC. |
|
| December 29, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT NVDLRT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 20, 2010 NOVADEL PHARMA INC. |
|
| November 19, 2010 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* NovaDel Pharma Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 66986X 10 6 (CUSIP Number) Jay Moorin ProQuest Investments 90 Nassau Street, 5th Floor Princeton, NJ 08542-4520 (781) 762-0123 (Name, Address and Telephone Number of Person Authorized to |
|
| November 12, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2010 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . COMMISSION FILE NO. 001-32177 NOVADEL |
|
| November 12, 2010 |
NovaDel Pharma Reports Recent Events and Financial Results for Third Quarter 2010 Exhibit 99.1 NovaDel Pharma Reports Recent Events and Financial Results for Third Quarter 2010 Bridgewater, NJ – November 12, 2010 - NovaDel Pharma Inc. (OTCBB: NVDL), a specialty pharmaceutical company developing oral spray formulations for a broad range of marketed pharmaceutical products, today reported recent events and financial results for the third quarter and nine months ended September 30 |
|
| November 12, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 12, 2010 NOVADEL PHARMA INC. |
|
| November 12, 2010 |
Prospectus Supplement filed under Rule 424(b)(3) in connection with Registration No. |
|
| November 5, 2010 |
As filed with the Securities and Exchange Commission on November 5, 2010 As filed with the Securities and Exchange Commission on November 5, 2010 Registration Statement No. |
|
| November 5, 2010 |
November 5, 2010 VIA EDGAR AND FEDERAL EXPRESS Mr. Jeffrey P. Riedler Assistant Director Securities and Exchange Commission 100 F Street, N.E., Mail Stop 4720 Washington, DC 20549 Re: NovaDel Pharma Inc. Registration Statement on Form S-1 Filed October 21, 2010 File No.: 333-170066 (the “Registration Statement”) Dear Mr. Riedler: On behalf of NovaDel Pharma Inc. (the “Company”), we are pleased to |
|
| November 4, 2010 |
NovaDel Pharma Inc. Receives $500,000 Milestone Payment Exhibit 99.1 NovaDel Pharma Inc. Receives $500,000 Milestone Payment Bridgewater, NJ – November 4, 2010 - NovaDel Pharma Inc. (OTCBB: NVDL) today announced that it has received a $500,000 milestone payment in connection with the license and distribution agreement, dated October 27, 2009, between NovaDel Pharma Inc. and Mist Acquisition, LLC. The agreement provides Mist Acquisition, LLC with a lice |
|
| November 4, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 4, 2010 NOVADEL PHARMA INC. |
|
| October 21, 2010 |
As filed with the Securities and Exchange Commission on October 21, 2010 As filed with the Securities and Exchange Commission on October 21, 2010 Registration Statement No. |
|
| October 15, 2010 |
Exhibit 99.1 NovaDel Pharma Inc. Announces Positive Data from Pilot Pharmacokinetic Study Comparing Duromist™ (sildenafil citrate oral spray) to Viagra® Tablet Oral Spray Technology Provides Increased Systemic Sildenafil Exposure Bridgewater, NJ – October 15, 2010 - NovaDel Pharma Inc. (OTCBB: NVDL), a specialty pharmaceutical company developing oral spray formulations for a broad range of markete |
|
| October 15, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 15, 2010 NOVADEL PHARMA INC. |
|
| August 16, 2010 |
Prospectus Supplement filed under Rule 424(b)(3) in connection with Registration No. |
|
| August 16, 2010 |
NovaDel Reports Financial Results for Second Quarter and Six Months ended June 30, 2010 Exhibit 99.1 NovaDel Reports Financial Results for Second Quarter and Six Months ended June 30, 2010 Bridgewater, NJ – August 16, 2010 - NovaDel Pharma Inc. (OTCBB: NVDL) (the “Company”), a specialty pharmaceutical company developing oral spray formulations for a broad range of prescription products, reported financial results for its second quarter and six months ended June 30, 2010. For the quar |
|
| August 16, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 10-Q 1 novadel10q63010.htm QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2010 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to |
|
| August 16, 2010 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 16, 2010 NOVADEL PHARMA INC. |
|
| June 30, 2010 |
7,583,335 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-167425 PROSPECTUS 7,583,335 Shares of Common Stock This prospectus relates to offers and resales or other dispositions by certain of our security holders or their transferees of up to 7,583,335 shares of our common stock, par value $0.001 per share, issuable upon the exercise of five year warrants and six month warrants each issued pu |
|
| June 28, 2010 |
Steven B. Ratoff Chairman, President and Chief Executive Officer NovaDel Pharma Inc. 1200 Route 22 East, Suite 2000 Bridgewater, NJ 08807 Tel. (908) 203-4640 Fax (908) 203-4744 [email protected] June 28, 2010 VIA FACSIMILE & EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jeffrey P. Riedler, Assistant Director Re: Nova |
|
| June 23, 2010 |
As filed with the Securities and Exchange Commission on June 23, 2010 Registration No. |
|
| June 22, 2010 |
As filed with the Securities and Exchange Commission on June 22, 2010 As filed with the Securities and Exchange Commission on June 22, 2010 Registration Statement No. |
|
| June 22, 2010 |
June 22, 2010 VIA EDGAR AND FEDERAL EXPRESS Mr. Jeffrey P. Riedler Assistant Director Securities and Exchange Commission 100 F Street, N.E., Mail Stop 4720 Washington, DC 20549 Re: NovaDel Pharma Inc. Registration Statement on Form S-1 Filed June 9, 2010 File No.: 333-167425 (the “Registration Statement”) Dear Mr. Riedler: On behalf of NovaDel Pharma Inc. (the “Company”), we are pleased to provide |
|
| June 10, 2010 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 10, 2010 NOVADEL PHARMA INC. |
|
| June 10, 2010 |
NOVADEL PHARMA INC. 2006 EQUITY INCENTIVE PLAN (AS AMENDED AND RESTATED ON APRIL 20, 2010) Exhibit 10.1 NOVADEL PHARMA INC. 2006 EQUITY INCENTIVE PLAN (AS AMENDED AND RESTATED ON APRIL 20, 2010) This NovaDel Pharma Inc. 2006 Equity Incentive Plan (the “Plan”) has been approved by the Board of Directors of NovaDel Pharma Inc., a Delaware corporation (the “Company”) and subject to approval by the stockholders of the Company, and became effective as of the Effective Date. Section 1. Purpos |
|
| June 9, 2010 |
As filed with the Securities and Exchange Commission on June 9, 2010 As filed with the Securities and Exchange Commission on June 9, 2010 Registration Statement No. |
|
| June 9, 2010 |
NovaDel Pharma Inc. Positioned for Growth Annual Meeting June 10, 2010 Forward Looking Statement Except for historical information contained herein, this presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks and uncertainties that may cause the Company's actual results or outc |
|
| June 9, 2010 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) June 9, 2010 NOVADEL PHARMA INC. |
|
| June 9, 2010 |
Exhibit 99.1 NovaDel Pharma Inc. Announces Appointment of Craig Johnson as Senior Vice President, Chief Financial Officer and Secretary Bridgewater, NJ – June 9, 2010 - NovaDel Pharma Inc. (OTCBB: NVDL), today announced the appointment of Craig Johnson as Senior Vice President, Chief Financial Officer and Secretary effective June 16, 2010. Steven B. Ratoff, Chairman, President and Chief Executive |
|
| June 9, 2010 |
EX-10.1 2 exhibit10-1.htm EMPLOYMENT AGREEMENT Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is entered into on June 8, 2010 (the “Execution Date”) and is effective as of June 16, 2010 (the “Effective Date”), by and between NovaDel Pharma, Inc. (the “Company”), and Craig Johnson (the “Executive”). The Company and the Executive are hereinafter collectively referred t |
|
| June 9, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 8, 2010 NOVADEL PHARMA INC. |
|
| May 17, 2010 |
NovaDel Reports Financial Results for First Quarter ended March 31, 2010 Exhibit 99.1 NovaDel Reports Financial Results for First Quarter ended March 31, 2010 Bridgewater, NJ – May 17, 2010 NovaDel Pharma Inc. (OTCBB: NVDL) (the “Company”), a specialty pharmaceutical company developing oral spray formulations for a broad range of marketed treatments, reported financial results for its first quarter ended March 31, 2010. For the quarter ended March 31, 2010, NovaDel rep |
|
| May 17, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) May 17, 2010 NOVADEL PHARMA INC. |
|
| May 17, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2010 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . COMMISSION FILE NO. 001-32177 NOVADEL PHA |
|
| April 28, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confide |
|
| April 28, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confide |
|
| April 1, 2010 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* NovaDel Pharma Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 66986X 10 6 (CUSIP Number) Jay Moorin ProQuest Investments 90 Nassau Street, 5th Floor Princeton, NJ 08542-4520 (781) 762-0123 (Name, Address and Telephone Number of Person Authorized to |
|
| March 31, 2010 |
NOVADEL PHARMA, INC. Common Stock and Warrants PLACEMENT AGENT AGREEMENT Exhibit 1.1 NOVADEL PHARMA, INC. Common Stock and Warrants PLACEMENT AGENT AGREEMENT March 31, 2010 Chardan Capital Markets, LLC 17 State Street, Suite 1600 New York, NY 10004 Ladies and Gentlemen: NovaDel Pharma, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to certain investors (collectively, the “Investors” or “Buyers”) up to an aggregate of (a) 9,100,001 shares (the |
|
| March 31, 2010 |
Filed Pursuant to Rule 424(b)(5) Under the Securities Act of 1933, as amended (Registration Statement No. |
|
| March 31, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 26, 2010 NOVADEL PHARMA INC. |
|
| March 31, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [ X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2009 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NO. 001-32177 NOVADEL PHARMA INC. (Exact Name of registrant as specified in its |
|
| March 31, 2010 |
EX-10.1 6 c60872ex10-1.htm Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of March 31, 2010, is by and among Novadel Pharma Inc., a Delaware corporation with offices located at 1200 Route 22 East, Suite 2000, Bridgewater, NJ 08807 (the “Company”), and each of the investors listed on the Schedule of Buyers attached hereto (individually, a “ |
|
| March 31, 2010 |
[FORM OF SERIES A WARRANT] NOVADEL PHARMA INC. WARRANT TO PURCHASE COMMON STOCK Exhibit 4.1 [FORM OF SERIES A WARRANT] NOVADEL PHARMA INC. WARRANT TO PURCHASE COMMON STOCK Series A Warrant No.: Date of Issuance: March 31, 2010 (“Issuance Date”) Novadel Pharma Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [IROQUOIS MASTER FUND LTD.] [OTHER BUYERS], the regi |
|
| March 31, 2010 |
NovaDel Announces $1.5 Million Equity Financing Exhibit 99.1 NovaDel Announces $1.5 Million Equity Financing Bridgewater, NJ – March 31, 2010 NovaDel Pharma Inc. (OTCBB: NVDL) announced today that it has entered into a securities purchase agreement to raise approximately $1.5 million in gross proceeds through the sale of approximately 9 million shares of its common stock to selected institutional investors at a price of $0.165 per share. The in |
|
| March 31, 2010 |
[FORM OF SERIES B WARRANT] NOVADEL PHARMA INC. WARRANT TO PURCHASE COMMON STOCK Exhibit 4.2 [FORM OF SERIES B WARRANT] NOVADEL PHARMA INC. WARRANT TO PURCHASE COMMON STOCK Series B Warrant No.: Date of Issuance: March 31, 2010 (“Issuance Date”) Novadel Pharma Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [IROQUOIS MASTER FUND LTD.][OTHER BUYERS], the regis |
|
| March 31, 2010 |
EXHIBIT 10.2 TERMINATION AGREEMENT This TERMINATION AGREEMENT (this “Termination Agreement”) is entered as of March 26, 2010 (the “Effective Date”), by and between NovaDel Pharma Inc., a Delaware corporation (the “Company”), and Seaside 88, LP, a Florida limited partnership (such investor, including its successors and assigns, “Seaside”, together with the Company, the “Parties”). WHEREAS, the Comp |
|
| March 5, 2010 |
NovaDel Reports Financial Results for Year Ended December 31, 2009 Exhibit 99.1 NovaDel Reports Financial Results for Year Ended December 31, 2009 Bridgewater, NJ – March 4, 2010 - NovaDel Pharma Inc. (the “Company”) (OTCBB: NVDL), a specialty pharmaceutical company developing oral spray formulations for a number of marketed products, reported financial results for the year ended December 31, 2009. For the year ended December 31, 2009, the Company reported a net |
|
| March 5, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 4, 2010 NOVADEL PHARMA INC. |
|
| March 1, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 26, 2010 NOVADEL PHARMA INC. |
|
| January 15, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 15, 2010 NOVADEL PHARMA INC. |
|
| January 15, 2010 |
c599588k.htm - Converted by SEC Publisher, created by BCL Technologies Inc., for SEC Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 14, 2010 NOVADEL PHARMA INC. (Exact Name of Registrant as Specified in Its Charter) D |
|
| January 15, 2010 |
Exhibit 10.1 Office Service Agreement Agreement Date (mm/dd/yy): 12 / 7 / 2009 Reference No.: 8192-96243 Business Center Address: Bridgewater Center 1180 1200 US Route 22 East, Ste 2000 Bridgewater, NJ 08807 Client Address (Not a Regus Center Address): Company Name: Novadel Pharmaceutical Contact Name: David Bergstrom Address: 25 Minneakoning Rd Address: Flemington NJ 08822 Phone & Email: 908-782- |
|
| January 11, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) January 11, 2010 NOVADEL PHARMA INC. |
|
| January 11, 2010 |
Exhibit 10.1 EXECUTION VERSION EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is entered into on January 8, 2010 (the “Execution Date”) and is effective as of January 1, 2010 (the “Effective Date”), by and between NovaDel Pharma, Inc. (the “Company”), and Steven B. Ratoff (the “Executive”). The Company and the Executive are hereinafter collectively referred to as the “Parties,” a |
|
| January 11, 2010 |
NOVADEL APPOINTS STEVEN B. RATOFF PRESIDENT AND CHIEF EXECUTIVE OFFICER Exhibit 99.1 NOVADEL APPOINTS STEVEN B. RATOFF PRESIDENT AND CHIEF EXECUTIVE OFFICER Flemington, NJ – January 11, 2010 Novadel Pharma, Inc. (the “Company”) (OTCBB: NVDL) announced that the Company’s Board of Directors has appointed Steven B. Ratoff as President and Chief Executive Officer effective January 1, 2010. Mr. Ratoff has been Chairman of the Board since September 2006, Interim President a |
|
| January 11, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) January 8, 2010 NOVADEL PHARMA INC. |
|
| January 11, 2010 |
NovaDel Pharma Inc. Positioned for Growth Exhibit 99.1 NovaDel Pharma Inc. Positioned for Growth NVDL.OB Forward Looking Statement Except for historical information contained herein, this presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks and uncertainties that may cause the Company's actual results or outcomes to |
|
| January 7, 2010 |
NOTE AND WARRANT AMENDMENT AGREEMENT Exhibit 10.1 NOTE AND WARRANT AMENDMENT AGREEMENT This NOTE AND WARRANT AMENDMENT AGREEMENT (this “Amendment”), dated as of December 31, 2009, by and among NovaDel Pharma Inc., a Delaware corporation (the “Company”), and ProQuest Investment II, L.P., ProQuest Investment Advisors Fund II, L.P. and ProQuest Investments III, L.P. (the “Holders”). WHEREAS, the Holders own certain promissory notes (the |
|
| January 7, 2010 |
NOVADEL ANNOUNCES AGREEMENT WITH DEBT HOLDER TO CONVERT THEIR NOTES TO EQUITY Exhibit 99.1 NOVADEL ANNOUNCES AGREEMENT WITH DEBT HOLDER TO CONVERT THEIR NOTES TO EQUITY Flemington, NJ – January 5, 2010 Novadel Pharma, Inc. (the “Company”) (OTCBB: NVDL) announces it has entered into an amendment agreement with ProQuest Investments L.P. and its affiliates (collectively, “ProQuest”) to convert the outstanding aggregate principal balance of all convertible notes and all liquida |
|
| January 7, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) December 31, 2009 NOVADEL PHARMA INC. |
|
| January 5, 2010 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* NovaDel Pharma Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 66986X 10 6 (CUSIP Number) Jay Moorin ProQuest Investments 90 Nassau Street, 5th Floor Princeton, NJ 08542-4520 (781) 762-0123 (Name, Address and Telephone Number of Person Authorized to |
|
| January 5, 2010 |
NOTE AND WARRANT AMENDMENT AGREEMENT EXHIBIT 10.3 NOTE AND WARRANT AMENDMENT AGREEMENT This NOTE AND WARRANT AMENDMENT AGREEMENT (this “Amendment”), dated as of December 31, 2009, by and among NovaDel Pharma Inc., a Delaware corporation (the “Company”), and ProQuest Investment II, L.P., ProQuest Investment Advisors Fund II, L.P. and ProQuest Investments III, L.P. (the “Holders”). WHEREAS, the Holders own certain promissory notes (the |
|
| December 28, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) December 24, 2009 NOVADEL PHARMA INC. |
|
| December 28, 2009 |
NovaDel Announces Listing on OTC Bulletin Board Exhibit 99.1 NovaDel Announces Listing on OTC Bulletin Board Flemington, NJ – December 24, 2009 - NovaDel Pharma Inc. (the “Company”) (OTCBB: NVDL) is pleased to announce that its common stock will begin trading on the Over-the-Counter Bulletin Board (“OTCBB”) on December 24, 2009. The Company’s new ticker symbol on OTCBB is NVDL. The Company filed Form 25 on December 14, 2009, voluntarily withdra |
|
| December 14, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-32177 Issuer: NOVADEL PHARMA INC. |
|
| December 10, 2009 |
Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as “***”. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission. Exhibit 10.2 License And Distribution Agreement By And Between NovaDel Pharma Inc. And ecr pharmaceut |
|
| December 10, 2009 |
License And Distribution Agreement Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as “***”. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission. Exhibit 10.1 License And Distribution Agreement By and Between NovaDel Pharma Inc. and Mist Acquisiti |
|
| December 10, 2009 |
Financial Statements and Exhibits, Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K/A (Amendment No. |
|
| December 3, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) December 2, 2009 NOVADEL PHARMA INC. |
|
| December 3, 2009 |
Exhibit 99.1 NovaDel Announces Voluntary Delisting from NYSE Amex LLC and Pending Transfer to the Over-the-Counter Bulletin Board Flemington, NJ – December 3, 2009 On December 2, 2009, NovaDel Pharma Inc. (the “Company”) (NYSE AMEX: NVD) notified NYSE Amex LLC (“Exchange”) of its intent of voluntarily delist its common stock from the Exchange. The Company anticipates that the delisting will be eff |
|
| December 1, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 24, 2009 NOVADEL PHARMA INC. |
|
| November 23, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 20, 2009 NOVADEL PHARMA INC. |
|
| November 17, 2009 |
NovaDel Reports Financial Results for Third Quarter and Nine Months ended September 30, 2009 Exhibit 99.1 NovaDel Reports Financial Results for Third Quarter and Nine Months ended September 30, 2009 Flemington, NJ – November 16, 2009 - NovaDel Pharma Inc. (the “Company”) (NYSE AMEX: NVD), a specialty pharmaceutical company developing oral spray formulations for a broad range of marketed treatments, reported financial results for its third quarter and nine months ended September 30, 2009. |
|
| November 17, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 16, 2009 NOVADEL PHARMA INC. |
|
| November 16, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) November 16, 2009 NOVADEL PHARMA INC. |
|
| November 16, 2009 |
Exhibit 99.1 NovaDel Signs Exclusive License and Distribution Agreement with Hi-Tech Pharmacal Co, Inc.’s Subsidiary to Commercialize and Manufacture ZolpiMist™ in the US and Canada Flemington, NJ – November 16, 2009 NovaDel Pharma Inc. (NYSE AMEX: NVD) today announced its entry into an exclusive license and distribution agreement with ECR Pharmaceuticals Company, Inc., a wholly owned subsidiary o |
|
| November 16, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2009 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . COMMISSION FILE NO. |
|
| November 9, 2009 |
8-K 1 form8k11909.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 6, 2009 NOVADEL PHARMA INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-32177 22-2407152 (State or other jurisdiction of incorpora |
|
| October 29, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 26, 2009 NOVADEL PHARMA INC. |
|
| October 29, 2009 |
NovaDel Licenses its NitroMist® Lingual Spray to Mist Exhibit 99.1 NovaDel Licenses its NitroMist® Lingual Spray to Mist Flemington, NJ – October 27, 2009 NovaDel Pharma Inc., (NYSE AMEX: NVD) has entered into a licensing agreement with privately-held Mist Acquisition, LLC to manufacture and commercialize the NitroMist® lingual spray version of nitroglycerine, a widely-prescribed and leading short-acting nitrate for the treatment of angina pectoris. |
|
| October 26, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 23, 2009 NOVADEL PHARMA INC. |
|
| October 16, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) October 15, 2009 NOVADEL PHARMA INC. |
|
| October 16, 2009 |
Safe Harbor Statement Except for historical information contained herein, this document may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. |
|
| October 16, 2009 |
Exhibit 99.2 NovaDel Holds Annual Meeting Flemington, NJ – October 16, 2009 NovaDel Pharma Inc. (NYSE AMEX: NVD) held its 2009 Annual Meeting of Stockholders on October 15, 2009. Mr. Mark Baric, Mr. Thomas Bonney, Mr. Steven Ratoff and Dr. Charles Nemeroff were elected directors of the Company. In addition, J.H. Cohn, LLP was approved as the Company’s auditors for 2009. Mr. Ratoff, Chairman of the |
|
| September 28, 2009 |
8-K 1 form8k92809.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 25, 2009 NOVADEL PHARMA INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-32177 22-2407152 (State or other jurisdiction of incorpo |
|
| September 14, 2009 |
8-K 1 form8k91409.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 11, 2009 NOVADEL PHARMA INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-32177 22-2407152 (State or other jurisdiction of incorpo |
|
| September 3, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confide |
|
| September 3, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definit |
|
| August 31, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 28, 2009 NOVADEL PHARMA INC. |
|
| August 24, 2009 |
Financial Statements and Exhibits, Other Events 8-K 1 form8kpr82409.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) August 24, 2009 NOVADEL PHARMA INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-32177 22-2407152 (State or other jurisdiction of incorpora |
|
| August 24, 2009 |
NovaDel Receives Milestone Payment from Velcera, Inc. Exhibit 99.1 NovaDel Receives Milestone Payment from Velcera, Inc. Flemington, NJ – August 24, 2009 On August 17, 2009, NovaDel Pharma Inc. (the “Company”) (NYSE AMEX: NVD) received a milestone payment of approximately $150,000 from Velcera, Inc. (“Velcera”) relating to its License and Development Agreement with Velcera dated June 22, 2004 (the “Agreement”). The Agreement provides Velcera with a l |
|
| August 17, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 14, 2009 NOVADEL PHARMA INC. |
|
| August 12, 2009 |
NovaDel Reports Financial Results for Second Quarter and Six Months ended June 30, 2009 Exhibit 99.1 NovaDel Reports Financial Results for Second Quarter and Six Months ended June 30, 2009 Flemington, NJ – August 12, 2009 - NovaDel Pharma Inc. (the “Company”) (NYSE AMEX: NVD), a specialty pharmaceutical company developing oral spray formulations for a broad range of marketed treatments, reported financial results for its second quarter and six months ended June 30, 2009. For the quar |
|
| August 12, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2009 or oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . COMMISSION FILE NO. 001-32177 NOVADEL PHARMA |
|
| August 12, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 12, 2009 NOVADEL PHARMA INC. |
|
| August 4, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 31, 2009 NOVADEL PHARMA INC. |
|
| July 20, 2009 |
NovaDel Receives Approval to Issue up to 12.0 Million Shares over the Next 12 Months Exhibit 99.1 NovaDel Receives Approval to Issue up to 12.0 Million Shares over the Next 12 Months Flemington, NJ – July 20, 2009 NovaDel Pharma Inc. (NYSE AMEX: NVD) received approval from the NYSE AMEX on July 16, 2009 to issue up to 12.0 million shares over the next twelve (12) months. On July 17, 2009, NovaDel executed the initial closing with Seaside 88, LP receiving gross proceeds of approxim |
|
| July 20, 2009 |
Appendix A INDEMNIFICATION AGREEMENT EX-10 3 exhibit10-172009x.htm Exhibit 10.1 ARTHUR W. WOOD COMPANY, INC. ARTHUR WOOD INVESTMENT ADVISORS May 27, 2009 This letter (this “Agreement”) sets forth the terms by which Novadel Pharma Inc. (the “Company”) retains Arthur W. Wood Company, Inc. (“AWW”) as a non-exclusive financial advisor for the purposes of selling securities in the Company. 1. The Advisory. AWW hereby agrees to assist the |
|
| July 20, 2009 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 17, 2009 NOVADEL PHARMA INC. |
|
| July 17, 2009 |
13,000,000 SHARES OF COMMON STOCK Filed Pursuant to Rule 424(b)(5) Under the Securities Act of 1933, as amended (Registration Statement No. |
|
| June 30, 2009 |
COMMON STOCK PURCHASE AGREEMENT Exhibit 10.1 COMMON STOCK PURCHASE AGREEMENT This Common Stock Purchase Agreement (this “Agreement”) is dated as of June 26, 2009, by and between NovaDel Pharma Inc., a Delaware corporation (the “Company”), and Seaside 88, LP, a Florida limited partnership (such investor, including its successors and assigns, “Seaside”). WHEREAS, subject to the terms and conditions set forth in this Agreement, the |
|
| June 30, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 26, 2009 NOVADEL PHARMA INC. |
|
| June 30, 2009 |
Exhibit 99.1 NovaDel Receives Commitment of Investment Fund to Purchase up to 13.0 Million Shares over the Next 12 Months Flemington, NJ – June 29, 2009 NovaDel Pharma Inc. (NYSE AMEX: NVD) entered into an agreement with Seaside 88, LP (“Seaside”). Under the terms of the agreement and subject to the approval of the NYSE AMEX, Seaside has committed to purchase up to 13.0 million NovaDel common shar |
|
| June 15, 2009 |
As filed with the Securities and Exchange Commission on June 15, 2009 As filed with the Securities and Exchange Commission on June 15, 2009 Registration Statement No. |
|
| May 26, 2009 |
As filed with the Securities and Exchange Commission on May 26, 2009 As filed with the Securities and Exchange Commission on May 26, 2009 Registration Statement No. |
|
| May 22, 2009 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* NovaDel Pharma Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 66986X 10 6 (CUSIP Number) Jay Moorin ProQuest Investments 90 Nassau Street, 5th Floor Princeton, NJ 08542-4520 (781) 762-0123 (Name, Address and Telephone Number of Person Authorized to |
|
| May 15, 2009 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 15, 2009 NOVADEL PHARMA INC. |
|
| May 15, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2009 or oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . COMMISSION FILE NO. 001-32177 NOVADEL PHARM |
|
| May 15, 2009 |
NovaDel Reports Financial Results for First Quarter 2009 Exhibit 99.1 NovaDel Reports Financial Results for First Quarter 2009 Flemington, NJ – May 15, 2009 - NovaDel Pharma Inc. (NYSE AMEX: NVD), a specialty pharmaceutical company developing oral spray formulations for a broad range of marketed treatments, reported financial results for its first quarter ended March 31, 2009. For the quarter ended March 31, 2009, NovaDel reported a net loss of $2.1 mil |
|
| May 12, 2009 |
Filed Pursuant to Rule 424(b)(3) Under the Securities Act of 1933, as amended (Registration Statement No. |
|
| May 7, 2009 |
NYSE AMEX LLC Determines NovaDel Made Reasonable Demonstration of Its Ability to Regain Compliance - November 16, 2009 Deadline to Regain Compliance Flemington, NJ – May 7, 2009 - NovaDel Pharma Inc. |
|
| May 7, 2009 |
- Converted by SEC Publisher, created by BCL Technologies Inc., for SEC Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 7, 2009 NOVADEL PHARMA INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-32177 |
|
| May 5, 2009 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* NovaDel Pharma Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 66986X 10 6 (CUSIP Number) Jay Moorin ProQuest Investments 90 Nassau Street, 5th Floor Princeton, NJ 08542-4520 (781) 762-0123 (Name, Address and Telephone Number of Person Authorized to |
|
| May 1, 2009 |
Exhibit 10.1 AMENDMENT TO LEASE DATED MARCH 19, 2002 BY AND BETWEEN MACEDO BUSINESS PARK II, LLC (LANDLORD) AND NOVADEL PHARMA, INC. (TENANT) 1. NovaDel Pharma, Inc. (hereinafter referred to as “NovaDel”) shall immediately turn over the cash in escrow in the amount of Two Hundred Twenty-Six Thousand 00/100 Dollars ($226,000.00) to Landlord (Macedo Business Park II, LLC) without recourse, which sum |
|
| May 1, 2009 |
CORRESP 1 filename1.htm May 1, 2009 VIA FACSIMILE & EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jeffrey P. Riedler, Assistant Director Re: NovaDel Pharma Inc. Registration Statement on Form S-3/A (File Number 333-155345) Dear Mr. Riedler: In accordance with Rule 461 under the Securities Act of 1933, as amended (the “ |
|
| May 1, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 28, 2009 NOVADEL PHARMA INC. |
|
| May 1, 2009 |
EX-10 3 exhibit10-25109.htm Exhibit 10.2 April 30, 2009 Deni M. Zodda, Ph.D. 440 Coldstream Dr. Berwyn, PA 19312 Re: Separation, Consulting and General Release Agreement Dear Dr. Zodda: This letter represents the agreement between NovaDel Pharma Inc. (“NovaDel Pharma” or the “Company”) and Deni M. Zodda (“you”) with respect to the April 30, 2009 termination of your employment (the “Agreement”). Ex |
|
| April 29, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 [ X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2008 COMMISSION FILE NO. 001-32177 NOVADEL PHARMA INC. (Exact name of registrant as s |
|
| April 14, 2009 |
NovaDel Pharma Inc. 25 Minneakoning Road Flemington, NJ 08822 CORRESP 1 filename1.htm NovaDel Pharma Inc. 25 Minneakoning Road Flemington, NJ 08822 (908)782-3431 April 14, 2009 VIA FACSIMILE & EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jeffrey P. Riedler, Assistant Director Re: NovaDel Pharma Inc. Registration Statement on Form S-3/A (File Number 333-155345) Dear Mr. Riedler: |
|
| April 6, 2009 |
As filed with the Securities and Exchange Commission on April 6, 2009 As filed with the Securities and Exchange Commission on April 6, 2009 Registration Statement No. |
|
| April 6, 2009 |
[NOVADEL PHARMA INC.] April 6, 2009 VIA EDGAR AND FAX Securities and Exchange Commission Division of Corporation Finance 100 F Street Washington, D.C. 20549 Mail Stop 6010 Attn: Jeffrey Riedler Re: NovaDel Pharma Inc. Registration Statement on Form S-3/A Filed February 2, 2009 File No. 333-155345 Dear Mr. Riedler: This letter is submitted on behalf of NovaDel Pharma Inc. (the “Company”) in respons |
|
| March 30, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) March 30, 2009 NOVADEL PHARMA INC. |
|
| March 30, 2009 |
NovaDel Reports Financial Results for the Year Ended December 31, 2008 Exhibit 99.1 NovaDel Reports Financial Results for the Year Ended December 31, 2008 Flemington, NJ – March 30, 2009 - NovaDel Pharma Inc. (NYSE Amex LLC: NVD), a specialty pharmaceutical company developing oral spray formulations for a broad range of marketed treatments, today reported financial results for the year ended December 31, 2008. For the year ended December 31, 2008, the Company reporte |
|
| March 30, 2009 |
Exhibit 4.6 PROMISSORY NOTE THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAWS AND NEITHER THE SECURITIES NOR ANY INTEREST THEREIN MAY BE OFFERED, SOLD, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION UNDER SUCH ACT OR AN EXEMPTION FROM REGISTRATION, |
|
| March 30, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [ X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2008 OR oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NO. 001-32177 NOVADEL PHARMA INC. (Exact Name of registrant as specified in its ch |
|
| March 25, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 19, 2009 NOVADEL PHARMA INC. |
|
| March 25, 2009 |
NOVADEL ANNOUNCES SENIOR MANAGEMENT CHANGES Exhibit 99.1 NOVADEL ANNOUNCES SENIOR MANAGEMENT CHANGES Flemington, NJ – March 25, 2009 – NovaDel Pharma Inc. (NYSE Amex: NVD), today announced Michael E. Spicer’s resignation, effective April 1, 2009, as Chief Financial Officer and Corporate Secretary of the Company, in order to accept a position at another company. “Michael has been an important and integral part of the management team of the C |
|
| March 6, 2009 |
Schedule 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No. 1) Under the Securities Exchange Act of 1934 NovaDel Pharma Inc. (Name of Issuer) Common Stock, $.001 per share (Title of Class of Securities) 66986X106 (CUSIP Number) March 6, 2009 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate box to |
|
| February 3, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 NovaDel Pharma Inc. (Name of Issuer) Common Stock, par value $.001 per share (Title of Class of Securities) 66986X106 (CUSIP Number) Lindsay A. Rosenwald, M.D. 787 Seventh Avenue New York, NY 10019 (212) 554-4300 (Name, Address and Telephone Number of Person Authorized to |
|
| February 3, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 1) Under the Securities Exchange Act of 1934 NovaDel Pharma Inc. (Name of Issuer) Common Stock, par value $.001 per share (Title of Class of Securities) 66986X106 (CUSIP Number) Lindsay A. Rosenwald, M.D. 787 Seventh Avenue New York, NY 10019 (212) 554-4300 (Name, Address and Telephone Number of Per |
|
| February 3, 2009 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Amendment No. 6) Under the Securities Exchange Act of 1934 NovaDel Pharma Inc. (Name of Issuer) Common Stock, par value $.001 per share (Title of Class of Securities) 66986X106 (CUSIP Number) Lindsay A. Rosenwald, M.D. 787 Seventh Avenue New York, NY 10019 (212) 554-4300 (Name, Address and Telephone Number of Person Authorized |
|
| February 2, 2009 |
As filed with the Securities and Exchange Commission on February 2, 2009 As filed with the Securities and Exchange Commission on February 2, 2009 Registration Statement No. |
|
| February 2, 2009 |
Total Gross Proceeds Payable to Company(1) From the Office of Michael E. Spicer Chief Financial Officer and Corporate Secretary NovaDel Pharma, Inc. 25 Minneakoning Road Flemington, NJ 08822 Tel. (908) 782-3431 Ext. 2550 Fax (908) 782-2445 [email protected] VIA EDGAR AND FAX Securities and Exchange Commission Division of Corporation Finance 100 F Street Washington, D.C. 20549 Mail Stop 6010 Attn: Jeffrey Riedler Re: NovaDel Pharma Inc. R |
|
| January 30, 2009 |
NYSE Alternext US Grants Extension for NovaDel to Comply with Listing Requirements Exhibit 99.1 NYSE Alternext US Grants Extension for NovaDel to Comply with Listing Requirements Flemington, NJ – January 30, 2009 - NovaDel Pharma Inc. (NYSE Alternext: NVD), a specialty pharmaceutical company developing oral spray formulations for a broad range of marketed treatments, today announced that the Company received notice from the NYSE Alternext US LLC (NYSE Alternext US) that the NYSE |
|
| January 30, 2009 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 30, 2009 NOVADEL PHARMA INC. |
|
| January 28, 2009 |
8-K 1 c564818k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 22, 2009 NOVADEL PHARMA INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-32177 22-2407152 (State or other jurisdiction (Commission Fil |
|
| December 23, 2008 |
Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Schedule 13D with respect to the shares of common stock of NovaDel Pharma Inc. is, and any amendment thereto signed by each of the undersigned shall be, filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k) promulgated under the Securities Exchange Act of 1 |
|
| December 23, 2008 |
Exhibit 24 POWER OF ATTORNEY KNOW ALL MEN BY THESE PRESENTS, that each of the undersigned hereby constitutes and appoints, as of the date hereof, Pasquale DeAngelis, his or her true and lawful attorney-in-fact with full power of substitution, resubstitution and revocation, for the undersigned and in the undersigned's name, place and stead, in any and all capacities, including, but not limited to, |
|
| December 23, 2008 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* NovaDel Pharma Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 66986X 10 6 (CUSIP Number) Jay Moorin ProQuest Investments 90 Nassau Street, 5th Floor Princeton, NJ 08542-4520 (781) 762-0123 (Name, Address and Telephone Number of Person Authorized to R |
|
| December 23, 2008 |
Exhibit 24 POWER OF ATTORNEY KNOW ALL MEN BY THESE PRESENTS, that each of the undersigned hereby constitutes and appoints, as of the date hereof, Pasquale DeAngelis, his or her true and lawful attorney-in-fact with full power of substitution, resubstitution and revocation, for the undersigned and in the undersigned's name, place and stead, in any and all capacities, including, but not limited to, |
|
| December 22, 2008 |
Financial Statements and Exhibits, Other Events 8-K 1 form8kpr122208.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 22, 2008 NOVADEL PHARMA INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-32177 22-2407152 (State or other jurisdiction of incor |
|
| December 22, 2008 |
Exhibit 99.1 NovaDel Pharma Receives FDA Approval of Zolpimist™ - Second FDA Approval of a NovaMist™-based Product- FLEMINGTON, NJ, December 22, 2008 - NovaDel Pharma Inc. (AMEX: NVD) today announced that Zolpimist (zolpidem tartrate) 5 mg and 10 mg Oral Spray has been approved by the U.S. Food and Drug Administration (FDA) for the short-term treatment of insomnia characterized by difficulties wit |
|
| December 17, 2008 |
SC 13G/A 1 nova13ga.htm NOVA13GA20081217 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No.3) UNDER THE SECURITIES EXCHANGE ACT OF 1934 NOVADEL PHARMA INC. (Name of Issuer) Common Shares (Title of Class of Securities) 669 86X 106 (CUSIP Number) Philip Boudreau Caisse de dépôt et placement du Québec 1000 place Jean-Paul-Riopelle, Montreal (Quebec), H2Z 2B3 Tel.: |
|
| November 13, 2008 |
As filed with the Securities and Exchange Commission on November 13, 2008 S-3 1 novadels-3111308.htm As filed with the Securities and Exchange Commission on November 13, 2008 Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NovaDel Pharma Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 2834 22-2407152 (State or other jurisdiction o |
|
| November 12, 2008 |
NovaDel Reports Financial Results for Third Quarter 2008 Exhibit 99.1 NovaDel Reports Financial Results for Third Quarter 2008 Flemington, NJ – November 12, 2008 - NovaDel Pharma Inc. (AMEX: NVD), a specialty pharmaceutical company developing oral spray formulations for a broad range of marketed treatments, reported financial results for its third quarter ended September 30, 2008. For the quarter ended September 30, 2008, NovaDel reported a net loss of |
|
| November 12, 2008 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 form8kearnings111208.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) November 12, 2008 NOVADEL PHARMA INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-32177 22-2407152 (State or other jurisdiction of |
|
| November 12, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2008 or oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . COMMISSION FILE NO. 001-32177 NOVADEL P |
|
| October 21, 2008 |
Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 17, 2008 NOVADEL PHARMA INC. |
|
| October 21, 2008 |
NovaDel Closes on $2,525,000 of Financing with ProQuest Investments LLC Exhibit 99.1 NovaDel Closes on $2,525,000 of Financing with ProQuest Investments LLC Flemington, NJ, October 21, 2008 – NovaDel Pharma Inc. (AMEX: NVD) announced today that on October 17, 2008, it closed on the remaining $2,525,000 (the “Subsequent Closing”) of its previously announced private placement of up to $4.0 million in secured convertible promissory notes and accompanying warrants with Pr |
|
| September 19, 2008 |
NovaDel Pharma Announces PDUFA Deadline Extension on Zolpimist™ Exhibit 99.1 NovaDel Pharma Announces PDUFA Deadline Extension on Zolpimist™ Flemington, NJ, September 18, 2008 - NovaDel Pharma Inc. (AMX: NVD) today announced that the U.S. Food and Drug Administration (FDA) has requested an extension of up to 3 months on the Prescription Drug User Fee Act (PDUFA) deadline in order to complete the review of the Company’s Zolpimist (zolpidem tartrate) Oral Spray |
|
| September 19, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) September 18, 2008 NOVADEL PHARMA INC. |
|
| September 11, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) September 8, 2008 NOVADEL PHARMA INC. |
|
| September 8, 2008 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) September 8, 2008 NOVADEL PHARMA INC. |
|
| September 8, 2008 |
CORPORATE PRESENTATION Safe Harbor Statement Except for historical information contained herein, this document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. |
|
| September 4, 2008 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) September 4, 2008 NOVADEL PHARMA INC. |
